跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

AMAG PHARMACEUTICALS, INC.

首页临床试验发起方与机构AMAG PHARMACEUTICALS, INC.

AMAG PHARMACEUTICALS, INC.

ACTIVE

61 Mooney St, 马萨诸塞州米德尔塞克斯县, Massachusetts, 美国www.amagpharma.comSubsidiary440 名员工成立于: 1981-01-01

别名:

amag

隶属于 covis group sarl

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

81

50 进行中

药物批准

8

批准总数

监管机构

2

监管机构数

成立时间

1981

概览

试验阶段分布

阶段

试验数

占比

1 期

30

37.0%

3 期

17

21.0%

2 期

6

7.4%

不适用

3

3.7%

4 期

1

1.2%

试验状态分布

进行中（未招募）

50

61.7%

已完成

16

19.8%

招募中

4

4.9%

终止

6

7.4%

Unknown

2

2.5%

相关临床试验

该机构主办的试验（81）

A research study to evaluate the experimental drug AMAG-423 to see how well it works and how safe it is in women who are near child birth who develop a condition called severe preeclampsia.

进行中（未招募）

Mar 2022200 名受试者

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

Oct 202141 名受试者

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

Sep 201975 名受试者

A research study to evaluate the experimental drug AMAG-423 to see how well it works and how safe it is in women who are near child birth who develop a condition called severe preeclampsia.

进行中（未招募）

Jun 2019200 名受试者

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

Jun 2019228 名受试者

A research study to evaluate the experimental drug AMAG-423 to see how well it works and how safe it is in women who are near child birth who develop a condition called severe preeclampsia.

进行中（未招募）

Jun 2019200 名受试者

A research study to evaluate the experimental drug AMAG-423 to see how well it works and how safe it is in women who are near child birth who develop a condition called severe preeclampsia.

进行中（未招募）

Mar 2019200 名受试者

Research study to evaluate the experimental drug ferumoxytol, to see how well it works for children with iron deficiency anemia (IDA) or who are at risk of developing IDA, and to see how safe it is compared to another marketed iron product – iron sucrose.

进行中（未招募）

Mar 201975 名受试者

第 1 页，共 11 页

药物批准

按机构分类的批准

FDA

Food and Drug Administration

7

药物批准

CANADA

Health Canada

1

药物批准

近期批准

资讯

Formation Bio Strengthens Leadership Team with Former Pfizer and BenevolentAI Executives to Advance AI-Driven Drug Development

- Formation Bio appointed four senior executives including Louis Brenner, MD as Chief Medical Officer and Daniel Neil, PhD as Chief Technology Officer to strengthen its AI-native pharmaceutical model. - Former Pfizer CFO Frank D'Amelio and ex-Incyte CSO Dashyant Dhanak, PhD joined as Strategic Advisors to guide the company's drug licensing and acquisition decisions. - The leadership expansion supports Formation Bio's plan to grow its pipeline from current assets to 10-15 drug candidates over the next 3-5 years. - The company recently secured a €545M out-licensing deal and added a new autoimmune disease asset to its development portfolio.

本页目录

概览
相关临床试验81
药物批准8
资讯1

返回机构列表